Arginine methyltransferase 6 inhibitor as well as preparation method, pharmaceutical composition and application thereof

By developing a new arginine methyltransferase 6 inhibitor, the problem that the existing technology cannot effectively regulate the PRMT6 protein level is solved, the treatment of diseases related to abnormal PRMT6 expression is realized, and new anti-tumor drug selection is provided. And the preparation method is simple, safe and easy to implement.

CN119080685AActive Publication Date: 2024-12-06SICHUAN UNIV

Patent Information

Application Number
CN202410322127.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-03-20
Publication Date
2024-12-06
Estimated Expiration
2044-03-20

AI Technical Summary

Technical Problem

Existing PRMTs inhibitors are unable to effectively selectively degrade arginine methyltransferase 6 (PRMT6), thereby regulating its protein levels, and there is a lack of effective treatment options for diseases related to abnormal PRMT6 expression.

Method used

A novel arginine methyltransferase 6 inhibitor has been developed, which has a specific chemical structure and preparation method, and can selectively degrade PRMT6 for the prevention or treatment of tumors and other diseases related to abnormal PRMT6 expression.

Benefits of technology

This inhibitor is obtained based on design and synthetic screening, has anti-tumor cell activity, can effectively degrade PRMT6 protein, provides a new anti-tumor drug development choice, and is simple, safe and easy to produce in industrialized manner.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080685A_ABST
    Figure CN119080685A_ABST
Patent Text Reader

Abstract

The invention provides an arginine methyltransferase 6 inhibitor as well as a preparation method, a pharmaceutical composition and application thereof, and relates to the technical field of biological medicines. The arginine methyltransferase 6 inhibitor provided by the invention is a new compound obtained on the basis of large-scale design, synthesis and screening, the arginine methyltransferase 6 inhibitor is different from an existing PRMTs inhibitor, the arginine methyltransferase 6 inhibitor can selectively degrade arginine methyltransferase 6, and the arginine methyltransferase 6 inhibitor can be used for preparing a PRMTs inhibitor. The protein level of the arginine methyltransferase 6 is regulated and controlled, and the arginine methyltransferase 6 has anti-tumor cell activity, can be used for preventing or treating PRMT6 expression abnormity related diseases, and provides a new choice for development and application of anti-tumor drugs. According to the preparation method of the arginine methyltransferase 6 inhibitor, the adopted raw materials are easy to obtain, the synthesis method is simple, safe, easy to implement and high in yield, and industrial production can be achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biomedicine technology, and in particular to an arginine methyltransferase 6 inhibitor and a preparation method, a pharmaceutical composition and use thereof. Background Art

[0002] Epigenetics involves DNA methylation, histone modification, chromatin remodeling, and non-coding RNA. Epigenetic dysregulation is a common feature of most cancers, and cancer often occurs directly by changing epigenetic mechanisms. Arginine methylation is a common post-translational modification that can serve as an epigenetic regulator of transcription and plays a vital role in DNA damage signaling, precursor messenger RNA splicing, cell signaling, and messenger RNA translation.

[0003] The arginine methyltransferase family (PRMTs) is a key enzyme involved in the protein arginine methylation process, and nine PRMTs members have been found in mammalian cells. By regulating different forms of arginine methylation, PRMTs can be divided into three categories: type I, type II, and type III. PRMT6 is a member of the type I PRMTs family and is the most important protein for the methylation of Arg2 (H3R2) of histone H3. It is involved in episodic regulation of gene expression, DNA repair, alternative splicing, cell proliferation and aging, and DNA methylation. In addition, PRMT6 can methylate non-histone substrates such as CRAF, PTEN, BAG5, p21, and GPS2. Abnormal expression of PRMT6 is associated with the occurrence and development of a variety of diseases. In summary, the development of new PRMT6 inhibitor molecules is of great significance. Summary of the invention

[0004] The purpose of the present application is to provide an arginine methyltransferase 6 inhibitor and its preparation method, pharmaceutical composition and use to solve the above problems.

[0005] To achieve the above objectives, this application adopts the following technical solutions:

[0006] The present application first provides an arginine methyltransferase 6 inhibitor having a structure shown in Formula I:

[0007]

[0008] Wherein, Z is pyridine, and the connection mode of pyridine is selected from

[0009] R1 and R2 are each independently H or CH3;

[0010] X is -CH2- or carbonyl, and Y is -CO-NH- or -NH-CO-;

[0011] Linker is an aliphatic chain or polyethylene glycol chain with a length of 1-11 carbons;

[0012] n is 0 or 1.

[0013] Preferably, the arginine methyltransferase 6 inhibitor is selected from one or more compounds represented by the following structural formulas:

[0014]

[0015]

[0016] The present application also provides a method for preparing an arginine methyltransferase 6 inhibitor, comprising:

[0017] The first raw material and the second raw material are subjected to a first condensation reaction under alkaline conditions to obtain a first intermediate product, wherein the structural formula of the first raw material is Y1 is an amino group or a carboxyl group, and the structural formula of the second raw material is X1 is an amino group or a carboxyl group, and n1 is any positive integer from 1 to 11;

[0018] The first intermediate product reacts under a first acidic condition to obtain a second intermediate product;

[0019] The second intermediate product and the third raw material undergo a second condensation reaction under alkaline conditions to obtain a third intermediate product, and the structural formula of the third raw material is n is 0 or 1;

[0020] The fourth raw material and the fifth raw material are subjected to a reductive amination reaction under the second acidic condition to obtain a fourth intermediate product, wherein the fourth raw material is 5-bromopyridine-3-carboxaldehyde, and the structural formula of the fifth raw material is R1 and R2 are each independently H or CH3;

[0021] subjecting the third intermediate product and the fourth intermediate product to a palladium-mediated coupling reaction under alkaline conditions to obtain a fifth intermediate product;

[0022] The fifth intermediate product is reacted under a third acidic condition to obtain the arginine methyltransferase 6 inhibitor.

[0023] Preferably, the condensation agents used in the first condensation reaction and the second condensation reaction are 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1-hydroxy-7-azobenzotriazole; the base used is N-methylmorpholine; the molar ratio of the first raw material, the second raw material, the base, the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and the 1-hydroxy-7-azobenzotriazole is 1:(1-3):(3-10):(1-3):(1-3); the molar ratio of the second intermediate product, the third raw material, the base, the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and the 1-hydroxy-7-azobenzotriazole is 1:(1-3):(3-10):(1-3):(1-3).

[0024] Preferably, the acid used in the first acidic condition and the third acidic condition is independently trifluoroacetic acid or hydrochloric acid; the molar ratio of the first intermediate product to the acid is 1:(3-10), and the molar ratio of the fifth intermediate product to the acid is 1:(3-10).

[0025] Preferably, the solvent for the reductive amination reaction is dichloromethane or dichloroethane; the acid used in the second acidic condition is glacial acetic acid; and the reductive amination agent used is sodium triacetoxyborohydride.

[0026] Preferably, the palladium is any one of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex, palladium acetate or tetrakis(triphenylphosphine)palladium; the base used in the coupling reaction is any one of sodium carbonate, potassium carbonate or cesium carbonate; the solvent used in the coupling reaction is a mixed solution of dioxane and water in a volume ratio of (5:1) to (1:1); the molar ratio of the third intermediate product, the fourth intermediate product, the palladium and the base is 1:(1-2):(0.05-0.15):(1-5).

[0027] Preferably, the reaction temperature of the reductive amination reaction is 0°C, the reaction temperature of the coupling reaction is 90-110°C, and the reaction temperature of the remaining reaction conditions is 5-25°C.

[0028] The present application also provides a pharmaceutical composition, comprising the above-mentioned arginine methyltransferase 6 inhibitor and pharmaceutically acceptable auxiliary components thereof.

[0029] The present application also provides the use of the above-mentioned arginine methyltransferase 6 inhibitor and the above-mentioned pharmaceutical composition in the preparation of a drug for preventing and / or treating diseases related to abnormal PRMT6 expression;

[0030] Preferably, the disease is a tumor, and the tumor is brain cancer, glioblastoma, leukemia, lymphoma, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast cancer, inflammatory breast cancer, Wilms' tumor, Ewing's sarcoma, rhabdomyosarcoma, ependymoma, medulloblastoma, colon cancer, gastric cancer, bladder cancer, head and neck cancer, kidney cancer, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma, osteosarcoma, giant cell tumor of bone or thyroid cancer.

[0031] Compared with the prior art, the beneficial effects of this application include:

[0032] The arginine methyltransferase 6 inhibitor provided in the present application is a new compound obtained on the basis of a large number of designed synthetic screenings. The arginine methyltransferase 6 inhibitor is different from the existing PRMTs inhibitors. The arginine methyltransferase 6 inhibitor can selectively degrade arginine methyltransferase 6, thereby regulating the protein level of arginine methyltransferase 6, has anti-tumor cell activity, can be used to prevent or treat diseases related to abnormal PRMT6 expression, and provides a new option for the development and application of anti-tumor drugs.

[0033] The preparation method of the arginine methyltransferase 6 inhibitor provided in the present application uses readily available raw materials, and the synthesis method is simple, safe, and easy to implement, with a high yield, and can be industrially produced. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 The results of the experimental inhibition of compound 8C on MDA-MB-435 cells and HCC827 cells;

[0035] Figure 2 The results show the effect of compound 8C on the colony-forming ability of MDA-MB-435 cells and HCC827 cells;

[0036] Figure 3 The results of PRMT6 protein degradation by compound 8C in MDA-MB-435 cells and HCC827 cells;

[0037] Figure 4 The results of compound 8C on PRMT6 protein degradation in MDA-MB-435 cells and HCC827 cells;

[0038] Figure 5 MDA-MB-435 cells were co-treated with the proteasome inhibitor MG132, the lysosome inhibitor chloroquine or EPZ020411, and immunoblotted with compound 8C;

[0039] Figure 6MDA-MB-435 cells and HCC827 cells were treated with 0, 10, and 20 μM of compound 8C for 72 hours, and then cell apoptosis was detected by flow cytometry. DETAILED DESCRIPTION

[0040] Example 1 Preparation of (4-oxo-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)amino)tert-butyl)carbamate (Compound 2C)

[0041] 4-Aminophenylboronic acid pinacol ester (500mg, 1.45mmol), tert-butyl methyl (2-(methylamino) ethyl) carbamate (354mg, 1.74mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (501mg, 2.61mmol), 1-hydroxy-7-azobenzotriazole (HOAT) (355.7mg, 2.61mmol), N-methylmorpholine (0.74mL, 7.26mmol) were added to 20mL dimethyl sulfoxide (DMSO) and reacted at room temperature overnight. After the reaction was completed by TLC detection, the reaction solution was poured into ice water and extracted with dichloromethane. The organic phase was collected, concentrated, and the target product was obtained by column chromatography. 620mg yellow solid, yield: 75.8%.

[0042] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ8.94(d,J=1.8Hz,1H),8.84(d,J=2.3Hz,1H),8.74(s,1H),8.39(t,J= 2.1Hz, 1H), 6.92 (t, J = 5.8Hz, 1H), 3.29 (d, J = 6.4Hz, 2H), 3.11 (q, J = 6.1Hz, 2H), 1.37 (s, 9H).

[0043] The structural formula is as follows:

[0044] Example 2 Preparation of 2-amino-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide (Compound 2A)

[0045] The target compound was obtained as a pale yellow solid with a yield of 74.68% using 4-aminophenylboronic acid pinacol ester and BOC-glycine in a reaction similar to that of compound 2C.

[0046] The NMR data are as follows: 1H NMR (400MHz, DMSO-d6) δ10.03(s,1H),7.60(s,4H),7.04(t,J=6.1Hz,1H),3.75(d,J=6.1Hz,2H),1.39(s,9H),1.28(s,12H).

[0047] The structural formula is as follows:

[0048] Example 3 Preparation of 3-amino-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanamide (Compound 2B)

[0049] The target compound was obtained as a pale yellow solid with 4-aminophenylboronic acid pinacol ester and Boc-β-alanine in a reaction similar to that of compound 2C. The yield was 76.26%.

[0050] The NMR data are as follows: 1 H NMR(400MHz,DMSO-d6)δ10.03(s,1H),7.64–7.57(m,4H),6.86(t,J=5.8Hz,1 H),3.22(q,J=6.9Hz,2H),2.48(d,J=7.1Hz,2H),1.37(s,9H),1.28(s,12H).

[0051] The structural formula is as follows:

[0052] Example 4 Preparation of 5-amino-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pentanamide (Compound 2D)

[0053] The target compound was obtained as a pale yellow solid with a yield of 78.58% using 4-aminophenylboronic acid pinacol ester and Boc-5-aminopentanoic acid through a reaction similar to that of compound 2C.

[0054] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ9.95 (s, 1H), 7.62–7.56 (m, 4H), 6.77 (t, J = 5.7Hz, 1H), 2.92 (q, J = 6.6Hz, 2H), 2.30 (t, J=7.4Hz, 2H), 1.55 (p, J=7.2Hz, 2H), 1.45–1.38 (m, 2H), 1.36 (s, 9H), 1.27 (s, 12H).

[0055] The structural formula is as follows:

[0056] Example 5 Preparation of 6-amino-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)hexanamide (Compound 2E)

[0057] Using 4-aminophenylboronic acid pinacol ester and tert-butyloxycarbonyl 6-aminocaproic acid, a reaction similar to that of compound 2C was performed to obtain the target compound g as a light yellow solid with a yield of 76.57%.

[0058] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.03 (s, 1H), 7.64–7.57 (m, 4H), 6.75d, J = 6.4Hz, 1H), 2.89 (d ,J=6.6Hz,2H),2.31(t,J=7.5Hz,2H),1.61–1.54(m,2H),1.37(s,13H),1.28(s,12H).

[0059] The structural formula is as follows:

[0060] Example 6 Preparation of 7-amino-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)heptylamide (Compound 2F)

[0061] The target compound was obtained as a pale yellow solid with 4-aminophenylboronic acid pinacol ester and BOC-7-aminoheptanoic acid through a reaction similar to that of compound 2C. The yield was 77.65%.

[0062] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.03 (s, 1H), 7.63–7.57 (m, 4H), 6.75d, J = 6.4Hz, 1H), 2.90 (d, J=6.6Hz,2H),2.31(t,J=7.5Hz,2H),1.58(t,J=7.5Hz,2H),1.36(s,15H),1.28(s,12H).

[0063] The structural formula is as follows:

[0064] Example 7 Preparation of 8-amino-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)octanamide (Compound 2G)

[0065] The target compound was obtained as a pale yellow solid with a yield of 78.28% using 4-aminophenylboronic acid pinacol ester and BOC-8-aminooctanoic acid through a reaction similar to that of compound 2C.

[0066] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.02 (s, 1H), 7.63–7.56 (m, 4H), 6.75d, J = 6.4Hz, 1H), 2.89 (q, J=6.6Hz,2H),2.30(t,J=7.5Hz,2H),1.58(t,J=7.5Hz,2H),1.35(s,21H),1.28(s,12H).

[0067] The structural formula is as follows:

[0068] Example 8 Preparation of 12-amino-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)dodecanoamide (Compound 2H)

[0069] The target compound was obtained as a pale yellow solid with 4-aminophenylboronic acid pinacol ester and 12-(BOC-amino) dodecanoic acid through a reaction similar to that of compound 2C in a yield of 78.74%.

[0070] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.10(s,1H),7.96(s,1H),7.65–7.58(m,4H),6.74(s,2H),3.70(t,J=6.2Hz,2H),3.64–3.58 (m,2H),3.51(s,5H),3.46(s,2H),3.05(t,J=6.2Hz,4H),2.57(d,J=5.4Hz,3H),1.37(d,J=2.8Hz,15H),1.28(s,12H).

[0071] The structural formula is as follows:

[0072] Example 9 Preparation of tert-butyl 2-(2-(3-oxo-3-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)amino)propyl)ethoxy)ethyl)carbamate (Compound 2I)

[0073] The target compound was obtained as a pale yellow solid with a yield of 80.68% using 4-aminophenylboronic acid pinacol ester and N-tert-butyloxycarbonyl-triethylene glycol-carboxylic acid through a reaction similar to that of compound 2C.

[0074] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.10(s,1H),7.96(s,1H),7.65–7.58(m,4H),6.74(s,2H),3.70(t,J=6.2Hz,2H),3.64–3.58 (m,2H),3.51(s,5H),3.46(s,2H),3.05(t,J=6.2Hz,4H),2.57(d,J=5.4Hz,3H),1.37(d,J=2.8Hz,15H),1.28(s,12H).

[0075] The structural formula is as follows:

[0076] Example 10 Preparation of N-(3-aminopropyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Compound 2J)

[0077] Using 4-carboxyphenylboronic acid pinacol ester and N-tert-butyloxycarbonyl-1,3-propylenediamine as raw materials, the target compound was obtained as a white solid with a yield of 88% through a reaction similar to that of the synthetic compound 2C.

[0078] The NMR data are as follows: 1 H NMR(400MHz, DMSO-d6)δ8.53(t,J=5.6Hz,1H),7.88–7.83(m,2H),7.77–7.70(m,3H), 3.27(q,J=6.6Hz,2H),3.08(q,J=6.6Hz,2H),1.82(s,2H),1.38(s,9H),1.28(s,12H).

[0079] The structural formula is as follows:

[0080] Example 11 Preparation of 4-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)butanamide (Compound 4C)

[0081] Step 1 Preparation of 4-amino-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)butyramide

[0082] (4-oxo-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)amino)tert-butyl)carbamate (Compound 2C) (500 mg, 1.28 mmol) and trifluoroacetic acid (2.94 ml, 3.84 mmol) of Example 1 were added to 20 ml of dichloromethane (CH2Cl2) and reacted overnight at room temperature. After the reaction was completed by monitoring by TLC, the target product was obtained by concentration under vacuum. 371 mg of brown liquid, yield: 100%. The target product does not need to be purified and can be used directly in the next step. Its structural formula is as follows:

[0083]

[0084] Step 2 Preparation of 4-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)butanamide

[0085] Compound 4-amino-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)butanamide (500 mg, 1.64 mmol), 1-adamantaneacetic acid (383 mg, 1.97 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (565.7 mg, 2.95 mmol), 1-hydroxy-7-azobenzotriazole (HOAT) (403.4 mg, 2.95 mmol), N-methylmorpholine (0.83 mL, 8.19 mmol) was added to 20 mL of dimethyl sulfoxide (DMSO) and reacted at room temperature overnight. After the reaction was completed by TLC, the reaction solution was poured into ice water and extracted with dichloromethane. The organic phase was collected, concentrated, and the target product was obtained by column chromatography. 570 mg brown solid, yield: 66.8%.

[0086] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.02(s,1H),7.74–7.69(m,1H),7.63–7.56(m,4H),3.06(q,J=6.7Hz,2H),2.33(t,J=7.5Hz, 2H),1.92–1.88(m,3H),1.82(s,2H),1.70(t,J=7.3Hz,2H),1.65(d,J=12.4Hz,3H),1.59–1.53(m,9H),1.28(s,12H).

[0087] The structural formula is as follows:

[0088] Example 12 Preparation of 2-((3r, 5r, 7r)-adamantan-1-yl)-N-(2-oxo-2-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)amino)ethyl)acetamide (Compound 4A)

[0089] Using compound 2A of Example 2 and 1-adamantaneacetic acid as raw materials, a reaction similar to that for synthesizing compound 4C was performed to obtain the target compound as a white solid with a yield of 68%.

[0090] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.08(s,1H),7.80(t,J=5.7Hz,1H),7.60(q,J=8.5Hz,4H),3.75 (d,J=6.3Hz,2H),1.84(s,3H),1.60(d,J=12.2Hz,4H),1.58–1.51(m,10H),1.28(s,12H).

[0091] The structural formula is as follows:

[0092] Example 13 Preparation of 3-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (Compound 4B)

[0093] Using compound 2B of Example 3 and 1-adamantaneacetic acid as raw materials, a reaction similar to that for synthesizing compound 4C was performed to obtain the target compound as a white solid with a yield of 69%.

[0094] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.08(s,1H),7.80(t,J=5.7Hz,1H),7.60(q,J=8.5Hz,4H),3.30(d,J=6 .3Hz,2H),2.53(s,2H),1.84(s,3H),1.60(d,J=12.2Hz,4H),1.56–1.49(m,10H),1.28(s,12H).

[0095] The structural formula is as follows:

[0096] Example 14 Preparation of (3r, 5r, 7r)-N-(4-oxo-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)amino)butyl)adamantane-1-carboxamide (Compound 4D)

[0097] Using compound 2C of Example 1 and 1-adamantanecarboxylic acid as raw materials, a reaction similar to that for synthesizing compound 4C was performed to obtain the target compound as a white solid with a yield of 68%.

[0098] The NMR data are as follows: 1 H NMR(400MHz, DMSO-d6)δ9.97(s,1H),7.63–7.57(m,4H),7.33(t,J=5.7Hz,1H),3.34(q,J=6 .6Hz,2H),2.31(t,J=7.3Hz,2H),1.98(d,J=2.9Hz,5H),1.68–1.62(m,10H),1.28(s,12H).

[0099] The structural formula is as follows:

[0100] Example 15 Preparation of N-(3-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)propyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Compound 4E)

[0101] Using compound 2J of Example 10 and 1-adamantaneacetic acid as raw materials, the target compound was obtained as a white solid through a reaction similar to that of synthesizing compound 4C with a yield of 70%.

[0102] The NMR data are as follows: 1 H NMR(400MHz, DMSO-d6)δ8.53(t,J=5.6Hz,1H),7.88–7.83(m,2H),7.77–7.70(m,3H),3.27(q,J=6.6Hz,2H),3.08 (q,J=6.6Hz,2H),1.93–1.88(m,3H),1.82(s,2H),1.64(dd,J=8.9,5.4Hz,5H),1.59–1.53(m,9H),1.31(s,12H).

[0103] The structural formula is as follows:

[0104] Example 16 Preparation of 5-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pentanamide (Compound 4F)

[0105] Using compound 2D of Example 4 and 1-adamantaneacetic acid as raw materials, a reaction similar to that for synthesizing compound 4C was performed to obtain the target compound as a white solid with a yield of 70%.

[0106] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.01(s,1H),7.76–7.62(m,1H),7.63–7.56(m,4H),3.06(q,J=6.7Hz,2H),2.32(t ,J=7.5Hz,2H),1.90–1.87(m,3H),1.82(s,2H),1.65(d,J=12.0Hz,5H),1.60–1.53(m,11H),1.28(s,12H).

[0107] The structural formula is as follows:

[0108] Example 17 Preparation of (3r, 5r, 7r)-N-(5-oxo-5-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)amino)pentyl)adamantane-1-carboxamide (Compound 4G)

[0109] Using compound 2D of Example 4, 1-adamantanecarboxylic acid as raw material, a reaction similar to that for synthesizing compound 4C was performed to obtain the target compound as a white solid with a yield of 71%.

[0110] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ9.97(s,1H),7.63–7.57(m,4H),7.33(t,J=5.7Hz,1H),3.04(q,J=6.6Hz,2H),2.31(t,J=7.3 Hz,2H),1.95(d,J=2.9Hz,3H),1.68–1.62(m,10H),1.54(dd,J=9.1,6.1Hz,2H),1.42(q,J=7.1Hz,2H),1.28(s,12H).

[0111] The structural formula is as follows:

[0112] Example 18 Preparation of 6-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)hexanamide (Compound 4H)

[0113] Using compound 2E of Example 5 and 1-adamantaneacetic acid as raw materials, a reaction similar to that for synthesizing compound 4C was performed to obtain the target compound as a white solid with a yield of 72%.

[0114] The NMR data are as follows: 1 H NMR(400MHz, DMSO-d6)δ9.97(s,1H),7.61(dd,J=11.7,3.1Hz,5H),3.01(q,J=6.6Hz,2H),2.30(t,J=7.4Hz,2H), 1.89(s,3H),1.79(d,J=3.3Hz,2H),1.63(d,J=12.0Hz,5H),1.58–1.50(m,11H),1.43–1.37(m,2H),1.28(s,12H).

[0115] The structural formula is as follows:

[0116] Example 19 Preparation of 7-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)heptylamide (4I)

[0117] Using compound 2F of Example 6 and 1-adamantaneacetic acid as raw materials, a reaction similar to that of synthesizing compound 4C was performed to obtain the target compound as a white solid with a yield of 72%.

[0118] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ9.98 (s, 1H), 7.66–7.57 (m, 5H), 3.00 (q, J = 6.4Hz, 2H), 2.30 (t, J = 7.4Hz, 2H), 1.90 (d ,J=4.6Hz,3H),1.79(s,2H),1.64(d,J=12.4Hz,4H),1.59–1.52(m,12H),1.38(t,J=6.7Hz,2H),1.28(s,14H).

[0119] The structural formula is as follows:

[0120] Example 20 Preparation of 8-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)octanamide (Compound 4J)

[0121] Using compound 2G of Example 7 and 1-adamantaneacetic acid as raw materials, a reaction similar to that for synthesizing compound 4C was performed to obtain the target compound as a white solid with a yield of 69%.

[0122] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ9.97(s,1H),7.66–7.56(m,5H),3.00(q,J=6.5Hz,2H),2.30(t,J=7.4Hz,2H),1.89(q,J=3.7,3.2H z,3H),1.79(d,J=1.9Hz,2H),1.63(d,J=12.0Hz,5H),1.55(dd,J=12.3,3.3Hz,11H),1.37(t,J=6.6Hz,2H),1.28(s,16H).

[0123] The structural formula is as follows:

[0124] Example 21 Preparation of 11-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)undecylamide (Compound 4K)

[0125] The compound 2H,1-adamantaneacetic acid in Example 8 was used as the raw material, and a reaction similar to that for synthesizing compound 4C was performed to obtain the target compound as a white solid with a yield of 70%.

[0126] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ9.97(s,1H),7.61(dd,J=7.8,3.4Hz,5H),3.00(q,J=6.3Hz,2H),2.31(t,J=7.4Hz,2H),1.91(d ,J=5.0Hz,3H),1.80(s,2H),1.68–1.61(m,5H),1.59–1.53(m,11H),1.36(t,J=6.6Hz,2H),1.28(s,12H),1.24(s,12H).

[0127] The structural formula is as follows:

[0128] Example 22 Preparation of 3-(2-(2-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)ethoxy)ethoxy)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (Compound 4L)

[0129] Using compound 2I of Example 9, 1-adamantaneacetic acid as raw material, a reaction similar to that for synthesizing compound 4C was performed to obtain the target compound as a white solid with a yield of 72%.

[0130] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.07(s,1H),7.69(t,J=5.8Hz,1H),7.65–7.57(m,4H),3.69(t,J=6.2Hz,2H),3.52–3.44(m,8H),2.57(t, J=6.2Hz,2H),2.50(p,J=1.9Hz,2H),1.89(t,J=3.1Hz,3H),1.81(s,2H),1.64(d,J=11.7Hz,4H),1.58–1.52(m,10H),1.28(s,12H).

[0131] The structural formula is as follows:

[0132] Example 23 Preparation of tert-butyl (2-(((5-bromopyridin-3-yl)methyl)(methyl)amino)ethyl)(methyl)carbamate (Compound 6A)

[0133] 5-Bromopyridine-3-carboxaldehyde (400mg, 2.15mmol), methyl (2-(methylamino)ethyl) carbamic acid tert-butyl ester (607mg, 3.23mmol), glacial acetic acid (738μM, 12.90mmol) were added to dichloroethane, and sodium triacetoxyborohydride (911mg, 4.30mmol) was added in batches at 0°C. The reaction solution was reacted at room temperature overnight. After the reaction was completed by TLC monitoring, saturated sodium bicarbonate solution was added to adjust the pH to 7-8, dichloromethane was added for extraction, and the organic phase was collected. The target compound was obtained by column chromatography. 400mg of light yellow oily liquid, yield 51.9%.

[0134] The NMR data are as follows: 1H NMR(400MHz, DMSO-d6)δδ8.58(d,J=2.3Hz,1H),8.47(d,J=1.9Hz,1H),7.93(t,J=2.0Hz,1H),3.53(s,2H),3. 27(d,J=8.6Hz,2H),2.82–2.69(m,3H),2.45(d,J=6.6Hz,2H),2.18(d,J=12.6Hz,3H),1.35(d,J=28.7Hz,9H).

[0135] The structural formula is as follows:

[0136] Example 24 Preparation of tert-butyl (2-(((5-bromopyridin-3-yl)methyl)(methyl)amino)ethyl)carbamate (Compound 6B)

[0137] Using 5-bromopyridine-3-carboxaldehyde as the starting material, the target compound was obtained as a white solid through a reaction similar to that of compound 6A with a yield of 53%.

[0138] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ8.58(d,J=2.3Hz,1H),8.47(d,J=1.7Hz,1H),7.93(t,J=2.0Hz,1H),6.42(s,2H),3 .53(s,2H),3.26(d,J=6.2Hz,2H),2.80–2.71(m,3H),2.45(d,J=6.6Hz,2H),1.36(dd,J=23.1,5.7Hz,9H).

[0139] The structural formula is as follows:

[0140] Example 25 Preparation of tert-butyl (2-(((5-bromopyridin-3-yl)methyl)amino)ethyl)(methyl)carbamate (Compound 6C)

[0141] Using 5-bromopyridine-3-carboxaldehyde as the starting material, the target compound was obtained as a white solid through a reaction similar to that of compound 6A with a yield of 54%.

[0142] The NMR data are as follows: 1H NMR (400MHz, DMSO-d6) δ8.56(d,J=2.3Hz,1H),8.50(d,J=1.7Hz,1H),8.00(t,J=2.0Hz,1H),3.74(s,2H),3 .23(t,J=6.6Hz,2H),2.78(s,3H),2.60(t,J=6.6Hz,2H),1.91(s,3H),1.45–1.30(dd,J=23.1,5.7Hz,9H).

[0143] The structural formula is as follows:

[0144] Example 26 Preparation of tert-butyl (2-(((6-bromopyridin-2-yl)methyl)(methyl)amino)ethyl)(methyl)carbamate (Compound 6D)

[0145] Using 6-bromopyridine-2-carboxaldehyde as the starting material, the target compound was obtained as a white solid through a reaction similar to that of compound 6A with a yield of 56%.

[0146] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ7.79–7.68(m,1H),7.54–7.41(m,2H),3.61(s,2H),3.19(t,J=6.7Hz,2H),2 .78(s,3H),2.50(td,J=4.9,4.3,2.4Hz,2H),2.25(d,J=10.6Hz,3H),1.38(dd,J=23.1,5.7Hz,9H).

[0147] The structural formula is as follows:

[0148] Example 27 Preparation of tert-butyl (2-(((2-bromopyridin-4-yl)methyl)(methyl)amino)ethyl)(methyl)carbamate (Compound 6E)

[0149] Using 2-bromopyridine-4-carboxaldehyde as the starting material, the target compound was obtained as a white solid through a reaction similar to that of compound 6A with a yield of 56%.

[0150] The NMR data are as follows: 1H NMR (400MHz, DMSO-d6) δ8.31(dd,J=5.0,3.6Hz,1H),7.55(d,J=3.9Hz,1H),7.36(dd,J=6.4,5.1Hz,1H),3.54 (s,2H),3.27(q,J=6.6Hz,2H),2.77(s,3H),2.45(d,J=6.5Hz,2H),2.19(s,3H),1.36(dd,J=23.1,5.7Hz,9H).

[0151] The structural formula is as follows:

[0152] Example 28 Preparation of tert-butyl (2-(((5-bromopyridin-3-yl)methyl)(methyl)amino)ethyl)(methyl)carbamate (Compound 6F)

[0153] Using 4-bromopyridine-3-carboxaldehyde as the starting material, the target compound was obtained as a white solid through a reaction similar to that of compound 6A with a yield of 56%.

[0154] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ8.67(s,1H),8.49(d,J=4.9Hz,1H),7.47(d,J=4.9Hz,1H),3.59(s,2H),3.30(s, 2H), 2.78 (d, J = 12.5Hz, 3H), 2.51 (dd, J = 6.4, 4.6Hz, 2H), 2.25 (d, J = 10.9Hz, 3H), 1.34 (d, J = 24.2Hz, 9H).

[0155] The structural formula is as follows:

[0156] Example 29 Preparation of (2-(5-bromo-N-methylnicotinamido)ethyl)(methyl)carbamate (Compound 6G)

[0157] 5-Bromonicotinic acid (500mg, 2.48mmol), tert-butyl (2-aminoethyl) carbamate (475.3mg, 2.73mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (855.0mg, 4.46mmol), 1-hydroxy-7-azobenzotriazole (HOAT) (607.1mg, 4.46mmol), N-methylmorpholine (1.36mL, 12.40mmol) were added to 20mL dimethyl sulfoxide (DMSO) and reacted overnight at room temperature. After the reaction was completed by TLC detection, the reaction solution was poured into ice water and extracted with dichloromethane. The organic phase was collected, concentrated, and the target product was obtained by column chromatography. 420mg off-white liquid, yield 52.8%.

[0158] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ8.94(d,J=1.8Hz,1H),8.84(d,J=2.3Hz,1H),8.74(s,1H),8.39(t,J= 2.1Hz, 1H), 6.92 (t, J = 5.8Hz, 1H), 3.29 (d, J = 6.4Hz, 2H), 3.11 (q, J = 6.1Hz, 2H), 1.37 (s, 9H).

[0159] The structural formula is as follows:

[0160] Example 30 Preparation of 4-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)-N-(4-(5-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-3-yl)phenyl)butanamide (Compound 8C) Step 1 Preparation of tert-butyl (2-((5-(4-(4-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)butanamido)phenyl)pyridin-3-yl)methyl)(methyl)amino)ethyl)(methyl)carbamate (Compound 7C)

[0161] Compound 4C (170 mg, 0.52 mmol) of Example 11, Compound 6A (188 mg, 0.52 mmol) of Example 23, and sodium carbonate (223 mg, 2.08 mmol) were added to a mixed solution of dioxane / water = 4:1, and the nitrogen was replaced five times. Subsequently, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (37.6 mg, 0.05 mmol) was added, and the nitrogen was replaced five times. Heated at 100°C for 4 hours, concentrated under reduced pressure under vacuum conditions, extracted with ethyl acetate, and the organic layers were combined and purified by column chromatography with a mobile phase of dichloromethane: methanol = 20:1 to obtain the product as an off-white solid with a yield of 58%.

[0162] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.10(s,1H),8.75(d,J=2.3Hz,1H),8.43(d,J=1.9Hz,1H),8.0 5(t,J=5.8Hz,1H),7.91(t,J=2.0Hz,1H),7.75–7.65(m,4H),3.88(d,J=5.8Hz,2H),3.59 (s,2H),3.29(m,2H),2.75(d,J=17.9Hz,3H),2.46(s,2H),2.22(d,J=14.0Hz,3H),1.92 (d,J=5.2Hz,5H),1.66(d,J=12.1Hz,3H),1.60(d,J=2.8Hz,9H),1.31(d,J=20.7Hz,9H).

[0163] The structural formula is as follows:

[0164] Step 2 Preparation of 4-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(5-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-3-yl)phenyl)butanamide

[0165] Compound 7C (150 mg, 0.24 mmol) was added to 1 M ethanolic hydrochloric acid solution. The reaction was stirred at room temperature for 8 hours. After the reaction was detected by TLC, the crude product was obtained by concentrating under vacuum. The crude product was washed with dry ethyl acetate, then filtered and dried to obtain the final product. Pale yellow 117 mg, yield 93%.

[0166] The NMR data are as follows: 1 H NMR(400MHz,DMSO-d6)δ10.11(s,1H),8.77(s,1H),8.47(s,1H),7.97(s,1H),7.74(d ,J=9.3Hz,3H),7.69(d,J=8.4Hz,2H),4.09(s,1H),3.60(s,2H),3.17(s,2H),3.08(d, J=6.7Hz, 3H), 2.77 (t, J=6.0Hz, 2H), 2.36 (d, J=6.3Hz, 4H), 2.17 (s, 3H), 1.91 (s, 3H), 1.83 (s, 2H), 1.75–1.70 (m, 2H), 1.65 (d, J=12.5Hz, 3H), 1.58 (d, J=10.2Hz, 9H). HRMS m / z[M+H]+532.3643, calculated value: 532.3651.

[0167] The structural formula is as follows:

[0168] Example 31 Preparation of 2-((3r,5r,7r)-adamantan-1-yl)-N-((4-((5-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-3-yl)phenyl)amino)-2-oxoethyl)acetamide (Compound 8A)

[0169] Using compound 6A of Example 23 and compound 4A of Example 12 as raw materials, a reaction similar to that for synthesizing compound 8C was performed to obtain the target compound as a white solid with a yield of 57%.

[0170] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.10(s,1H),8.76(d,J=2.3Hz,1H),8.45(d,J=1.9Hz,1H) ,8.06(t,J=5.8Hz,1H),7.94(t,J=2.2Hz,1H),7.71(s,4H),3.89(d,J=5.8Hz,2H),3 .58(s,2H),2.59(t,J=6.4Hz,2H),2.45(t,J=6.2Hz,2H),2.26(s,3H),2.17(d,J=4. 7Hz,3H),1.93(d,J=5.8Hz,5H),1.66(d,J=12.1Hz,3H),1.60(d,J=2.9Hz,9H).HRMS m / z [M+H] + 504.3331, calculated value: 504.3338.

[0171] The structural formula is as follows:

[0172] Example 32 Preparation of 3-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(5-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-3-yl)phenyl)acrylamide (Compound 8B)

[0173] Using compound 6A of Example 23 and compound 4B of Example 13 as raw materials, a reaction similar to that for synthesizing compound 8C was performed to obtain the target compound as a white solid with a yield of 59%.

[0174] The NMR data are as follows: 1H NMR (400MHz, DMSO-d6) δ10.10(s,1H),8.76(d,J=2.3Hz,1H),8.45(d,J=1.9Hz,1H) ,8.06(t,J=5.8Hz,1H),7.94(t,J=2.2Hz,1H),7.71(s,4H),3.89(d,J=5.8Hz,2H),3 .58(s,2H),2.59(t,J=6.4Hz,2H),2.45(t,J=6.2Hz,2H),2.26(s,3H),2.17(d,J=4. 7Hz,3H),1.93(d,J=5.8Hz,5H),1.66(d,J=12.1Hz,3H),1.60(d,J=2.9Hz,9H).HRMS m / z [M+H] + 518.3491, calculated value: 518.3495.

[0175] The structural formula is as follows:

[0176] Example 33 Preparation of (3r, 5r, 7r)-N-(4-((4-((5-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-3-yl)phenyl)amino)-4-oxobutyl)adamantane-1-carboxamide (Compound 8D)

[0177] Using compound 6A of Example 23 and compound 4D of Example 14 as raw materials, a reaction similar to that for synthesizing compound 8C was performed to obtain the target compound as a white solid with a yield of 56%.

[0178] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.07(s,1H),8.75(d,J=2.3Hz,1H),8.44(d,J=1.9Hz,1H),7.9 3(d,J=2.2Hz,1H),7.74(d,J=8.8Hz,2H),7.68(d,J=8.5Hz,2H),7.37(d,J=5.5Hz,1H),3 .57(s,2H),3.11(q,J=6.6Hz,3H),2.62(t,J=6.3Hz,3H),2.48–2.42(m,3H),2.32(t,J=7.4Hz,2H),2.28(s,4H),2.16(d,J=4.5Hz,4H),1.94(s,3H),1.75(t,J=4.5Hz,8H).HRMS m / z[M+H]+518.3489, calculated value: 518.3495.

[0179] The structural formula is as follows:

[0180] Example 34 Preparation of 5-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(5-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-3-yl)phenyl)pentanamide (Compound 8E) Using Compound 6A of Example 23 and Compound 4F of Example 16 as raw materials, through a reaction similar to that for synthesizing Compound 8C, the target compound was obtained as a white solid with a yield of 57%.

[0181] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.03(s,1H),8.76(d,J=2.2Hz,1H),8.45(d,J=1.9Hz,1H),7.94(t,J=2 .2Hz,1H),7.73(d,J=8.8Hz,2H),7.71–7.65(m,3H),3.58(s,2H),3.05(q,J=6.7Hz,2H),2.65(t, J=6.3 Hz, 2H), 2.47 (q, J=2.6 Hz, 2H), 2.34 (t, J=7.3 Hz, 2H), 2.30 (s, 3H), 2.17 (d, J=4.6 Hz, 4H), 1.90 (s, 3H), 1.81 (s, 2H), 1.64 (d, J=12.0 Hz, 4H), 1.60–1.53 (m, 10H), 1.44 (q, J=7.3 Hz, 2H). HRMS m / z[M+H]+546.3810, calculated value: 546.3808.

[0182] The structural formula is as follows:

[0183] Example 35 Preparation of (3r, 5r, 7r)-N-(5-((4-((5-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-3-yl)phenyl)amino)-5-oxopentyl)adamantane-1-carboxamide (Compound 8F)

[0184] Using compound 6A of Example 23 and compound 4G of Example 17 as raw materials, a reaction similar to that for synthesizing compound 8C was performed to obtain the target compound as a white solid with a yield of 53%.

[0185] The NMR data are as follows: 1H NMR (400MHz, DMSO-d6) δ10.09(s,1H),8.76(d,J=2.2Hz,1H),8.46(d,J=1.8Hz,1H),7.96(d,J=2.2Hz,1H),7.7 5(d,J=8.8Hz,2H),7.68(d,J=8.7Hz,2H),7.38(t,J=5.7Hz,1H),3.59(s,2H),3.06(q,J=6.6Hz,2H),2.76(t,J= 6.2Hz,2H),2.53(d,J=6.3Hz,2H),2.35(d,J=6.3Hz,5H),2.17(s,3H),1.95(d,J=4.2Hz,3H),1.75(d,J=2.9Hz,6H),1.70–1.60(m,7H),1.56(q,J=7.5Hz,2H),1.45(q,J=7.3Hz,2H).HRMS m / z[M+H]+532.3643, calculated value: 532.3651.

[0186] The structural formula is as follows:

[0187] Example 36 Preparation of N-(3-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)propyl)-4-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-3-yl)benzamide (Compound 8G)

[0188] Using compound 6A of Example 23 and compound 4E of Example 15 as raw materials, a reaction similar to that for synthesizing compound 8C was performed to obtain the target compound as a white solid with a yield of 52%.

[0189] The NMR data are as follows: 1 H NMR(400MHz,DMSO-d6)δ8.84(d,J=2.3Hz,1H),8.59–8.51(m,2H),8.04(t,J=2.2Hz,1H),8 .00–7.95(m,2H),7.88–7.82(m,2H),7.73(t,J=5.7Hz,1H),3.60(s,2H),3.32(d,J=6.6Hz , 3H), 3.10(q, J=6.7Hz, 2H), 2.63(t, J=6.3Hz, 2H), 2.47(t, J=6.3Hz, 2H), 2.28(s, 3H), 2.18(s, 3H), 1.90(s, 3H), 1.83(s, 2H), 1.65(dd, J=12.7,5.1Hz, 5H), 1.60–1.53(m, 9H). HRMS m / z[M+H]+532.3649, calculated value: 532.3651.

[0190] The structural formula is as follows:

[0191] Example 37 Preparation of 4-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(5-((2-aminoethyl)(methyl)amino)methyl)pyridin-3-yl)phenyl)butanamide (Compound 8H)

[0192] Using compound 6B of Example 24 and compound 4C of Example 11 as raw materials, a reaction similar to that for synthesizing compound 8C was performed to obtain the target compound as a white solid with a yield of 57%.

[0193] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.08(s,1H),8.76(d,J=2.3Hz,1H),8.46(d,J=1.9Hz,1H),7.9 5(t,J=2.3Hz,1H),7.74(d,J=8.9Hz,3H),7.71–7.66(m,2H),3.58(s,2H),3.08(q,J=6. 7Hz, 3H), 2.70 (t, J = 6.5Hz, 3H), 2.41 (t, J = 6.4Hz, 2H), 2.16 (d, J = 4.4Hz, 4H), 1.91 (s, 3H), 1.83 (s, 2H), 1.72 (t, J = 7.3Hz, 2H), 1.65 (d, J = 11.8Hz, 4H), 1.60–1.54 (m, 9H). HRMS m / z [M+H] + 518.3488, calculated value: 518.3495. The structural formula is as follows:

[0194] Example 38 Preparation of 4-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(5-((2-(methylamino)ethyl)amino)methyl)pyridin-3-yl)phenyl)butanamide (8I)

[0195] Using compound 6C of Example 25 and compound 4C of Example 11 as raw materials, a reaction similar to that for synthesizing compound 8C was performed to obtain the target compound as a white solid with a yield of 54%.

[0196] The NMR data are as follows: 1H NMR (400MHz, DMSO-d6) δ10.07(s,1H),8.73(d,J=2.2Hz,1H),8.46(d,J=1.9Hz,1H),7 .98(d,J=2.3Hz,1H),7.73(d,J=8.5Hz,3H),7.68(d,J=8.7Hz,2H),3.77(s,2H),3.08( q, J = 6.6 Hz, 3H), 2.58 (t, J = 4.2 Hz, 5H), 2.35 (t, J = 7.5 Hz, 2H), 2.27 (s, 3H), 1.91 (s, 3H), 1.83 (s, 2H), 1.72 (t, J = 7.2 Hz, 2H), 1.65 (d, J = 12.3 Hz, 3H), 1.60–1.53 (m, 9H). HRMS m / z [M+H] + 518.3489, calculated value: 518.3495.

[0197] The structural formula is as follows:

[0198] Example 39 Preparation of 5-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(5-((2-aminoethyl)(methyl)amino)methyl)pyridin-3-yl)phenyl)pentanamide (Compound 8J)

[0199] Using compound 6B of Example 24 and compound 4F of Example 16 as raw materials, a reaction similar to that for synthesizing compound 8C was performed to obtain the target compound as a white solid with a yield of 52%.

[0200] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.05(s,1H),8.76(d,J=2.3Hz,1H),8.46(d,J=1.9Hz,1H),7.94(t,J=2.2Hz,1H),7.74 (d,J=8.8Hz,2H),7.69(td,J=7.6,6.4,4.1Hz,3H),3.57(s,2H),3.05(q,J=6.6Hz,2H),2.70(td,J=6.4,2.2Hz, 3H), 2.42 (dd, J = 6.4, 3.9 Hz, 2H), 2.35 (t, J = 7.4 Hz, 2H), 2.16 (d, J = 4.5 Hz, 4H), 1.89 (d, J = 4.1 Hz, 3H), 1.81 (s, 2H), 1.64 (d, J = 12.3 Hz, 5H), 1.59–1.53 (m, 9H), 1.45 (q, J = 7.0 Hz, 2H). HRMS m / z [M+H] + 532.3644, calculated value: 532.3651.

[0201] The structural formula is as follows:

[0202] Example 40 Preparation of 6-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(5-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-3-yl)phenyl)hexanamide (Compound 8K): Using compound 6A from Example 23 and compound 4H from Example 18 as raw materials, a reaction similar to that for synthesizing compound 8C was performed to give the target compound as a white solid in a yield of 57%.

[0203] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.11(s,1H),8.76(d,J=2.2Hz,1H),8.47(s,1H),7.98(s,1H),7.75(d, J=8.4Hz,2H),7.71(s,3H),3.60(s,2H),3.02(q,J=6.5Hz,2H),2.84(t,J=6.2Hz,2H),2.57(t,J =6.0Hz, 2H), 2.41(d, J=1.1Hz, 3H), 2.33(t, J=7.3Hz, 2H), 2.16(d, J=3.7Hz, 4H), 1.89(s, 3H), 1.80(s, 2H), 1.67–1.59(m, 5H), 1.57–1.52(m, 9H), 1.45–1.39(m, 2H), 1.30(t, J=7.6Hz, 2H). HRMS m / z[M+H]+560.3955, calculated value: 560.3964.

[0204] The structural formula is as follows:

[0205] Example 41 Preparation of 7-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(5-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-3-yl)phenyl)heptylamide (Compound 8L): Using Compound 6A of Example 23 and Compound 4I of Example 19 as raw materials, a reaction similar to that for synthesizing Compound 8C was performed to give the target compound as a white solid in a yield of 57%.

[0206] The NMR data are as follows: 1H NMR (400MHz, DMSO-d6) δ10.03(s,1H),8.75(d,J=2.2Hz,1H),8.45(d,J=1.9Hz,1H),7.93(t,J=2.2Hz,1H),7. 73(d,J=8.9Hz,2H),7.68(d,J=8.8Hz,2H),7.63(d,J=5.9Hz,1H),3.57(s,2H),3.02(t,J=6.3Hz,2H),2.61(t , J=6.3Hz,2H),2.46(dd,J=6.3,4.0Hz,2H),2.33(t,J=7.4Hz,2H),2.27(s,3H),2.17(d,J=4.4Hz,4H),1.90(s,3H),1.81(s,2H),1.64(d,J=12.6Hz,5H),1.58–1.54(m,9H),1.39(d,J=6.8Hz,2H),1.34–1.29(m,4H).HRMS m / z[M+H]+574.4115, calculated value: 574.4121.

[0207] The structural formula is as follows:

[0208] Example 42 Preparation of 8-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(5-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-3-yl)phenyl)octanamide (Compound 8M): Using Compound 6A of Example 23 and Compound 4J of Example 20 as raw materials, a reaction similar to that for synthesizing Compound 8C was performed to give the target compound as a white solid in a yield of 57%.

[0209] The NMR data are as follows: 1H NMR (400MHz, DMSO-d6) δ10.03(s,1H),8.75(d,J=2.3Hz,1H),8.45(d,J=1.9Hz,1H),7.94(d,J=2.3Hz,1 H),7.73(d,J=8.6Hz,2H),7.67(d,J=8.7Hz,2H),7.64(d,J=6.4Hz,1H),3.58(s,2H),3.04–2.99(m,2H), 2.64 (t, J = 6.3 Hz, 2H), 2.45 (dd, J = 6.6, 4.0 Hz, 2H), 2.33 (d, J = 7.4 Hz, 2H), 2.29 (s, 3H), 2.16 (d, J = 4.3 Hz, 4H), 1.88 (s, 3H), 1.80 (s, 2H), 1.62 (d, J = 12.5 Hz, 5H), 1.57–1.52 (m, 9H), 1.39 (d, J = 8.7 Hz, 2H). HRMS m / z [M+H] + 588.4269, calculated value: 588.4277.

[0210] The structural formula is as follows:

[0211] Example 43 Preparation of 12-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-(5-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-3-yl)phenyl)dodecanoamide (Compound 8N)

[0212] Using compound 6A of Example 23 and compound 4K of Example 21 as raw materials, a reaction similar to that for synthesizing compound 8C was performed to obtain the target compound as a white solid with a yield of 56%.

[0213] The NMR data are as follows: 1H NMR (400MHz, DMSO-d6) δ10.00(s,1H),8.75(d,J=2.3Hz,1H),8.45(d,J=1.9Hz,1H),7.93(d,J=2.3Hz,1H),7 .73(d,J=8.8Hz,2H),7.67(d,J=8.7Hz,2H),7.60(d,J=5.9Hz,1H),3.57(s,2H),2.99(q,J=6.5Hz,2H),2.63( t, J = 6.3 Hz, 2H), 2.45 (q, J = 2.6 Hz, 2H), 2.33 (d, J = 7.2 Hz, 2H), 2.29 (s, 3H), 2.16 (d, J = 4.4 Hz, 4H), 1.89 (s, 3H), 1.79 (s, 2H), 1.67–1.59 (m, 5H), 1.58–1.53 (m, 9H), 1.35 (d, J = 8.7 Hz, 2H), 1.28 (s, 4H), 1.24 (s, 10H). HRMS m / z [M+H] + 644.4895, calculated value: 644.4903.

[0214] The structural formula is as follows:

[0215] Example 44 Preparation of 3-(2-(2-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)ethoxy)ethoxy)-N-(4-(5-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-3-yl)phenyl)propanamide (Compound 8O)

[0216] Using compound 6A of Example 23 and compound 4L of Example 22 as raw materials, a reaction similar to that for synthesizing compound 8C was performed to obtain the target compound as a white solid with a yield of 55%.

[0217] The NMR data are as follows: 1H NMR(400MHz,DMSO-d6)δ10.12(s,1H),8.76(s,1H),8.46(s,1H),7.95(s,1H),7.72 (q,J=8.3Hz,5H),3.72(t,J=6.2Hz,2H),3.58(s,2H),3.52(s,9H),3.16(d,J=9.9Hz ,3H),2.67(t,J=6.3Hz,3H),2.60(d,J=5.9Hz,2H),2.31(s,3H),2.17(d,J=4.6Hz, 3H),1.89(s,3H),1.81(s,2H),1.63(d,J=11.3Hz,3H),1.55(d,J=12.6Hz,9H).HRMS m / z [M+H] + 650.4271, calculated value: 650.4281.

[0218] The structural formula is as follows:

[0219] Example 45 Preparation of 4-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-((6-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-2-yl)phenyl)butanamide (Compound 8P) Using Compound 6D of Example 26 and Compound 4C of Example 11 as raw materials, through a reaction similar to that for synthesizing Compound 8C, the target compound was obtained as a white solid with a yield of 54%.

[0220] The NMR data are as follows: 1 H NMR(400MHz,DMSO-d6)δ10.10(s,1H),8.02(d,J=8.5Hz,2H),7.72–7.69(m,3H),7.61(d,J =7.9Hz,3H),7.38(d,J=7.3Hz,1H),3.71(s,2H),3.08(q,J=6.6Hz,2H),2.83(t,J=6.2Hz, : 9H). HRMS m / z[M+H]+532.3645, calculated value: 532.3651.

[0221] The structural formula is as follows:

[0222] Example 46 Preparation of 4-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)-N-(4-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-2-yl)phenyl)butanamide (Compound 8Q)

[0223] Using compound 6E of Example 27 and compound 4C of Example 11 as raw materials, a reaction similar to that for synthesizing compound 8C was performed to obtain the target compound as a white solid with a yield of 55%.

[0224] The NMR data are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.08(s,1H),8.55(d,J=5.0Hz,1H),8.03(d,J=8.5Hz,2H),7.83( s,1H),7.71(d,J=8.6Hz,2H),7.66(s,1H),7.25(d,J=4.8Hz,1H),3.57(s,2H),3.11–3.06( m, 2H), 2.65–2.61 (m, 3H), 2.35 (t, J=7.4 Hz, 2H), 2.30 (s, 3H), 2.18 (d, J=5.3 Hz, 4H), 1.91 (s, 3H), 1.83 (s, 2H), 1.72 (t, J=7.2 Hz, 2H), 1.65 (d, J=12.3 Hz, 3H), 1.60–1.53 (m, 9H). HRMS m / z[M+H]+532.3644, calculated value: 532.3651.

[0225] The structural formula is as follows:

[0226] Example 47 Preparation of 4-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)-N-(4-((methyl(2-(methylamino)ethyl)amino)methyl)pyridin-3-yl)phenyl)butanamide (Compound 8R)

[0227] Using compound 6F of Example 28 and compound 4C of Example 11 as raw materials, a reaction similar to that for synthesizing compound 8C was performed to obtain the target compound as a white solid with a yield of 57%.

[0228] The NMR data are as follows: 1H NMR (400MHz, DMSO-d6) δ10.06(s,1H),8.50(d,J=5.0Hz,1H),8.37(s,1H),7.74(t,J=5.5 Hz,1H),7.71–7.66(m,2H),7.56(d,J=5.0Hz,1H),7.52(d,J=5.0Hz,2H),3.47(d,J=3.1H z, 2H), 3.09 (q, J = 6.6 Hz, 4H), 2.54 (d, J = 6.4 Hz, 3H), 2.37–2.33 (m, 5H), 2.04 (s, 3H), 1.90 (s, 3H), 1.83 (s, 2H), 1.75–1.71 (m, 2H), 1.65 (d, J = 12.4 Hz, 3H), 1.59–1.55 (m, 9H). HRMS m / z[M+H]+532.3645, calculated value: 532.3651.

[0229] The structural formula is as follows:

[0230] Example 48 Preparation of 5-(4-(4-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)butyramido)phenyl)-N-methyl-N-(2-(methylamino)ethyl)nicotinamide (Compound 8S)

[0231] Using compound 6G of Example 29 and compound 4C of Example 11 as raw materials, a reaction similar to that for synthesizing compound 8C was performed to obtain the target compound as a white solid with a yield of 54%.

[0232] The NMR data are as follows: 1 H NMR (400 MHz, DMSO-d6) δ 10.08 (s, 1H), 8.93 (s, 1H), 8.57–8.52 (m, 1H), 8.09 (s, 1H), 7.74 (s, 5H), 3.56 (s, 2H), 3.17 (s, 1H), 3.08 (q, J = 6.7 Hz, 3H), 2.77 (s, 2H), 2.38–2.33 (m, 4H), 2.11 (s, 3H), 1.91 (s, 3H), 1.82 (s, 2H), 1.72 (t, J = 7.3 Hz, 2H), 1.65 (d, J = 12.4 Hz, 3H), 1.59–1.54 (m, 9H). HRMS m / z [M+H]+ 546.3435, calculated value: 546.3444.

[0233] The structural formula is as follows:

[0234] Example 49 Experiment on the inhibition of proliferation of two tumor cell lines by compounds 8A-8S

[0235] MDA-MB-435 breast cancer cell line and HCC827 non-small cell lung cancer cell line were purchased from American Type Culture Collection (ATCC); RPMI 1640 medium and fetal bovine serum (FBS) were purchased from GIBICO, USA; penicillin and streptomycin were purchased from Dalian Bao Biotechnology Co., Ltd.; culture dishes and 96-well plates for cells were purchased from Corning; centrifuge tubes of various specifications were purchased from BD; MTT reagent was purchased from Donjindo, Japan.

[0236] HCC827 non-small cell lung cancer cell line and breast cancer cell line MDA-MB-435 were cultured in a 37°C, 5% CO2 incubator with conventional high-glucose RPMI1640 or DMEM complete medium containing 10% fetal bovine serum (FBS), 100 IU / mL penicillin, and 100 μg / ml streptomycin.

[0237] In order to detect the effect of new compounds on the proliferation of MDA-MB-435 breast cancer cell line and HCC827 non-small cell lung cancer cell line. Collect cells in the logarithmic growth phase, adjust the cell concentration to 1000-2000 / mL single cell suspension, and inoculate 100uL per well in a 96-well plate. Dilute the compound stock solution (10mM / L dissolved in DMSO) with culture medium to different concentrations using a three-fold dilution method. Add 100uL per well to a 96-well plate, the highest concentration is 10μM, the lowest concentration is 0.0015μM, set up 2 replicates for each drug concentration, and treat the cells with 0.1% DMSO culture medium and pure culture medium as negative controls, place in a cell culture incubator and continue to culture for 3 days, use MTT to detect the activity of mitochondrial succinate dehydrogenase in the cells, and calculate the half effective inhibitory concentration (IC) of the new compound on tumor cells. 50 ) value, and the results are shown in Table 1. In Table 1, the letter A represents IC 50 Values ​​>1μM to ≤10μM; letter B indicates IC 50 Values ​​>10μM to ≤20μM; letter C indicates IC 50 Values ​​>20 μM.

[0238] Table 1 Inhibitory effect of some compounds on proliferation of two tumor cell lines (MTT method)

[0239]

[0240] As can be seen from Table 1, multiple tested compounds 8A, 8C, 8J, 8L, 8M, 8N, and 8R showed strong proliferation inhibition activity against the two tumor cell lines, IC 50Value ≤10μM.

[0241] Example 50 The inhibitory effect of compound 8C on MDA-MB-435 cells and HCC827 cells was dose-dependent

[0242] The sources of cell lines, reagents and consumables were the same as those in Example 49; other reagents such as PI were purchased from Sigma (USA).

[0243] The new compound (8C) was used to conduct a more in-depth proliferation inhibition activity test on the MDA-MB-435 breast cancer cell line and the HCC827 non-small cell lung cancer cell line. Cells in the logarithmic growth phase were collected, and the cell concentration was adjusted to a single cell suspension of 1000-2000 cells / mL, and 100uL was inoculated in a 96-well plate per well. The compound stock solution (10mM / L dissolved in DMSO) was diluted to different concentrations with culture medium using a three-fold dilution method. A volume of 100uL per well was added to a 96-well plate, with the highest concentration being 10μM and the lowest concentration being 0.0015μM. Two replicate wells were set for each drug concentration, and cells were treated with culture medium containing 0.1% DMSO and pure culture medium as negative controls. The drug-containing culture medium was replaced every 3 days. The reported PRMT6 inhibitors EPZ020411 and Cpd.a25 were used as positive controls. After 6 consecutive days of action, the activity of mitochondrial succinate dehydrogenase in cells was detected by MTT, and the half effective inhibitory concentration (IC 50 )value.

[0244] from Figure 1 It can be seen that the inhibitory activity of compound 8C on MDA-MB-435 breast cancer cells and HCC827 non-small cell lung cancer cells increases with increasing concentration.

[0245] Example 51: Clone formation experiment of compound 8C on MDA-MB-435 cells and HCC827 cells

[0246] The sources of cell lines, reagents and consumables are exactly the same as those in Example 50.

[0247] In order to detect the inhibitory effect of the new compound 8C on the colony formation of MDA-MB-435 breast cancer cells and HCC827 non-small cell lung cancer cells, tumor cells in the logarithmic growth phase were cultured at a rate of 3-4×10 3 The cells were inoculated into a 6-well plate at a concentration of 100 cells / well. The next day, after the cells attached to the wall, the supernatant was aspirated and 2 mL of the prepared medium containing different concentrations of the compound was added. The cells were treated with a medium containing 0.1% DMSO as a negative control. The drug-containing medium was replaced every 3 days. After 6 consecutive days of action, the medium was discarded, and the cells were fixed with 4% paraformaldehyde solution for 20 minutes, washed with deionized water, and then stained with crystal violet for 15 minutes, washed and dried.

[0248] from Figure 2 It can be seen that after treating the cells with 0, 5, and 10 μM of compound 8C for 6 days, the colony-forming ability of MDA-MB-435 and HCC827 cells was significantly weakened, and the number and size decreased with the increase of drug concentration, showing a certain concentration dependence.

[0249] Example 52 Effect of Compound 8C on PRMT6 Protein Expression in MDA-MB-435 Cells and HCC827 Cells

[0250] The sources of cell lines, reagents and consumables were the same as those in Example 49; other reagents such as cell lysate were purchased from Sigma (USA).

[0251] In order to detect the degradation effect of the new compound 8C on PRMT6 protein in MDA-MB-435 cells and HCC827 cells, tumor cells in the logarithmic growth phase were cultured at a rate of 3-4×10 3 The concentration of cells / well was inoculated in a 6-well plate. The next day, after the cells adhered to the wall, the supernatant was aspirated, and 2 mL of the prepared culture medium containing different concentrations of compounds was added, and the cells were treated with a culture medium containing 0.1% DMSO as a negative control. The drug-containing culture medium was replaced every 3 days. After 6 consecutive days of action. The cell suspension and adherent cells were collected and lysed in RIPA buffer containing a mixture and phosphatase inhibitors (1 / 1000) for 1 hour. Then, the cell lysate was centrifuged at 13000 rpm at 4°C for 30 minutes, the supernatant was collected and the protein concentration was determined by the BCA method. Equal protein samples were separated on SDS-PAGE gels and transferred to nitrocellulose (NC) filters. The membrane was then incubated with relevant primary and secondary antibodies. Specific protein bands were detected by chemiluminescence.

[0252] from Figure 3 It can be seen that MDA-MB-435 and HCC827 cells were treated with 1.25, 2.5, 5, 10, and 20 μM of compound 8C for 6 days, and then the changes in PRMT6 protein levels were detected by WB experiments. Compound 8C can significantly induce the degradation of PRMT6 protein in MDA-MB-435 and HCC827 cells, and the effect is dose-dependent. Figure 4 It can be seen that MDA-MB-435 and HCC827 cells were treated with 20 μM compound 8C for 0.5, 1, 3, 5, and 7 days, and then the changes in PRMT6 protein levels were detected by WB experiments. Compound 8C can significantly induce the degradation of PRMT6 protein in MDA-MB-435 and HCC827 cells, and the effect is time-dependent.

[0253] Example 53 Compound 8C degrades PRMT6 protein via ubiquitination pathway

[0254] To investigate the potential mechanism of PRMT6 degradation by compound 8C, MDA-MB-435 cells were co-treated with the proteasome inhibitor MG132 and the lysosome inhibitor chloroquine and subjected to immunoblotting assays together with compound 8C. Figure 5 As shown in (A) and (B), MG132 reversed the degradation of compound 8C by inhibiting the cellular UPS pathway, while pretreatment with the lysosomal inhibitor chloroquine did not affect PRMT6 degradation, indicating that the proteasome plays a central role in the HyT-mediated degradation mechanism. Then, to investigate the competition between PRMT6 inhibitors and compound 8C for PRMT6 targets, MDA-MB-435 cells were co-treated with the PRMT6 inhibitor EPZ020411 and subjected to immunoblotting assays with compound 8C. Figure 5 As shown in (C), at the same concentration of EPZ020411 and compound 8C, the degradation of compound 8C was slightly reversed.

[0255] Example 53 Compound 8C induces apoptosis of MDA-MB-435 cells and HCC827 cells

[0256] The sources of cell lines, reagents and consumables are exactly the same as those in Example 50.

[0257] Study the effect of compounds on cell apoptosis by flow cytometry: Collect cells in the logarithmic phase and adjust the cell suspension concentration to 2-10×10 per well. 5 Cells were inoculated into 6-well plates, with a volume of 2 mL per well. After culturing in a 37°C, 5% CO2 incubator for 24 hours, the supernatant was carefully aspirated, and 2 mL of the prepared drug-containing culture medium was added to each well according to the concentration gradient, and a control group without drug was set up. The cells were cultured in a 37°C, 5% CO2 incubator for 72 hours. The cells were then treated according to the following method: (1) The cells in each well were collected and numbered in sequence according to the concentration into flow tubes, centrifuged at 4°C, 2000 r / min for 3 minutes, and the supernatant was discarded; (2) The cells were resuspended in 3 mL PBS, centrifuged in the same way, and the PBS was discarded; (3) The cells were stained with the Annexin V-fluorescein isothiocyanate (FITC) cell apoptosis detection kit (Roche, Indianapolis, IN, USA), mixed, and incubated at room temperature in the dark for 20 minutes; and detected by flow cytometry.

[0258] from Figure 6 It can be seen that MDA-MB-435 and HCC827 cells were treated with 0, 10, and 20 μM of compound 8C for 72 hours, and then the changes in cell apoptosis were detected by flow cytometry. Compound 8C can significantly induce apoptosis of tumor cells, and the effect is dose-dependent.

Claims

1. An arginine methyltransferase 6 inhibitor, characterized in that It has the structure shown in Formula I: Wherein, Z is pyridine, and the connection mode of pyridine is selected from R1 and R2 are each independently H or CH3; X is -CH2- or carbonyl, and Y is -CO-NH- or -NH-CO-; Linker is an aliphatic chain or polyethylene glycol chain with a length of 1-11 carbons; n is 0 or 1.

2. The arginine methyltransferase 6 inhibitor according to claim 1, characterized in that The arginine methyltransferase 6 inhibitor is selected from one or more compounds represented by the following structural formula:

3. A method for preparing an arginine methyltransferase 6 inhibitor, characterized in that: include: The first raw material and the second raw material are subjected to a first condensation reaction under alkaline conditions to obtain a first intermediate product, wherein the structural formula of the first raw material is Y1 is an amino group or a carboxyl group, and the structural formula of the second raw material is X1 is an amino group or a carboxyl group, and n1 is any positive integer from 1 to 11; The first intermediate product reacts under a first acidic condition to obtain a second intermediate product; The second intermediate product and the third raw material undergo a second condensation reaction under alkaline conditions to obtain a third intermediate product, and the structural formula of the third raw material is n is 0 or 1; The fourth raw material and the fifth raw material are subjected to a reductive amination reaction under the second acidic condition to obtain a fourth intermediate product, wherein the fourth raw material is 5-bromopyridine-3-carboxaldehyde, and the structural formula of the fifth raw material is R1 and R2 are each independently H or CH3; subjecting the third intermediate product and the fourth intermediate product to a palladium-mediated coupling reaction under alkaline conditions to obtain a fifth intermediate product; The fifth intermediate product is reacted under a third acidic condition to obtain the arginine methyltransferase 6 inhibitor.

4. The preparation method according to claim 3, characterized in that: The condensation agents used in the first condensation reaction and the second condensation reaction are 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1-hydroxy-7-azobenzotriazole; the base used is N-methylmorpholine; the molar ratio of the first raw material, the second raw material, the base, the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and the 1-hydroxy-7-azobenzotriazole is 1:(1-3):(3-10):(1-3):(1-3); the molar ratio of the second intermediate product, the third raw material, the base, the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and the 1-hydroxy-7-azobenzotriazole is 1:(1-3):(3-10):(1-3):(1-3).

5. The preparation method according to claim 3, characterized in that: The acid used in the first acidic condition and the third acidic condition is independently trifluoroacetic acid or hydrochloric acid; the molar ratio of the first intermediate product to the acid is 1:(3-10), and the molar ratio of the fifth intermediate product to the acid is 1:(3-10).

6. The preparation method according to claim 3, characterized in that: The solvent for the reductive amination reaction is dichloromethane or dichloroethane; the acid used in the second acidic condition is glacial acetic acid; and the reductive amination agent used is sodium triacetoxyborohydride.

7. The preparation method according to claim 3, characterized in that: The palladium is any one of [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex, palladium acetate or tetrakis(triphenylphosphine)palladium; the base used in the coupling reaction is any one of sodium carbonate, potassium carbonate or cesium carbonate; the solvent used in the coupling reaction is a mixed solution of dioxane and water in a volume ratio of (5:1) to (1:1); the molar ratio of the third intermediate product, the fourth intermediate product, the palladium and the base is 1:(1-2):(0.05-0.15):(1-5).

8. The preparation method according to claim 3, characterized in that: The reaction temperature of the reductive amination reaction is 0°C, the reaction temperature of the coupling reaction is 90-110°C, and the reaction temperature of the remaining reaction conditions is 5-25°C.

9. A pharmaceutical composition, characterized in that The invention comprises the arginine methyltransferase 6 inhibitor according to claim 1 or 2 and a pharmaceutically acceptable auxiliary component thereof.

10. Use of the arginine methyltransferase 6 inhibitor according to claim 1 or 2 and the pharmaceutical composition according to claim 9 in the preparation of a drug for preventing and / or treating diseases related to abnormal PRMT6 expression; Preferably, the disease is a tumor, and the tumor is brain cancer, glioblastoma, leukemia, lymphoma, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast cancer, inflammatory breast cancer, Wilms' tumor, Ewing's sarcoma, rhabdomyosarcoma, ependymoma, medulloblastoma, colon cancer, gastric cancer, bladder cancer, head and neck cancer, kidney cancer, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma, osteosarcoma, giant cell tumor of bone or thyroid cancer.

Citation Information

Patent Citations

  • Arginine methyltransferase inhibitors and uses thereof

    WO2017136699A1

Cited By

  • PRMT1 protein degradation agent modified by taking adamantane as hydrophobic group and application of PRMT1 protein degradation agent

    CN119684195A

  • A PRMT1 protein degradation agent modified with adamantane as a hydrophobic group and application thereof

    CN119684195B

  • Use of prmt6 inhibitors in the manufacture of a medicament for treating a retinal vascular damaging disease

    CN122998351A